Form4insider filings, from the source

SEC Form 4 · accession 0001209191-16-096104

Anacor Pharmaceuticals, Inc. · ANAC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Paul L Berns
Officer — President and CEO · Director
Period of report
Feb 3, 2016
Accepted (ET)
Feb 5, 2016 · 7:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Feb 3, 2016A14,584$0.00A267,811D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F3$78.91Feb 3, 2016A73,788A—Feb 3, 2026Common Stock73,78873,788D
Performance Restricted Stock UnitsF4—Feb 3, 2016A14,584A——Common Stock14,58414,584D

Explanation of responses